Sofinnova closes €725M Crossover II fund for late-stage biotech

· VC Investment

TLDR

  • Sofinnova Partners closed Crossover II at €725M ($815M), above target, to back about 15 late-stage life sciences companies.12
  • The European Tech Champions Initiative, an EU-backed fund of funds, is the one named backer; Sofinnova names no other investors.13
  • The fund is about 63 per cent larger than the €445M Crossover I and already backs three companies.134

Sofinnova Partners, a life sciences venture capital firm based in Paris, London and Milan, announced the final close of Sofinnova Crossover II on 16 November 2026 at €725 million ($815 million), which it says exceeded its original target.1 The firm did not disclose that target.3 Reuters converted at $1 = €0.9073 and reported about $799 million; this article follows the release's dollar figure.2

A crossover fund, Reuters explains, "typically invests in private companies approaching commercialisation or public listings, bridging the gap between venture capital and public-market investing".2 Sofinnova says it backs clinical-stage biotech and medtech companies, "both public and private", with initial proof of concept.4 BioPharma Dive calls crossover financings private rounds that often precede an initial public offering, and quotes partner Kinam Hong: "Europe doesn't have an innovation problem, what it has is a scale-up financing problem."5

Crossover II will focus mainly on European clinical-stage biopharma and medtech companies, with investments in the United States and elsewhere, and expects to back about 15 companies.1 Hong told Fierce Biotech and BioXconomy that about 80 per cent will go to Europe, and Fierce says the fund will prioritise follow-on investment.67 Sofinnova declined to give its target initial cheque size or the share reserved for follow-ons.3 The fund has already backed Hemab Therapeutics, CellCentric and Neurent Medical.1 Fierce places them in Denmark (bleeding and clotting disorders), the UK (an oral oncology platform) and Ireland (a chronic rhinitis device); no amounts are given.6

On investors, the release says only that the fund is "backed by the European Tech Champions Initiative (ETCI), a fund of funds managed by the European Investment Fund (EIF)".1 The EIF describes ETCI as a fund-of-funds programme launched in 2023 by the EIB Group with six EU member states to invest in large venture capital and private equity funds.8 ETCI is therefore one public-backed limited partner in a privately managed fund. European Biotechnology reports sovereign funds, insurers and public institutions among the investors, with many returning from Crossover I according to Hong, but names none besides ETCI.3 Capital Finance, citing PitchBook, lists Ireland's sovereign fund ISIF and the NTMA pension scheme; Sofinnova has not confirmed this.9 The size of any commitment was not disclosed.

Crossover I closed at €445 million in 2021, according to Sofinnova.4 The release cites LimFlow (acquired by Inari Medical), Calliditas Therapeutics (Asahi Kasei), Amolyt Pharma (AstraZeneca) and Abivax (Nasdaq listing) as outcomes.1 European Biotechnology reports Sofinnova's claim, which is company-reported, that Crossover I's 16 companies later raised another €3.4 billion.3 The firm's flagship Capital XI closed at €650 million ($750 million) on 17 November 2025, ahead of its initial target, for early-stage biotech and medtech.10 Tech Funding News says rival Jeito Capital closed a €1 billion second fund in April.11 The release and Reuters put assets under management at over €4 billion; Fierce says more than €5 billion.126

Why it matters: the largest fund in Sofinnova's history adds a specialist pool of late-stage capital for European biotech, with an EU-backed fund of funds as the one named investor and the target, other backers and cheque sizes undisclosed.136

Sources

  1. Sofinnova Partners closes €725M Crossover II Fund (Sofinnova Partners)
  2. Sofinnova closes €725 million fund to back European biotech expansion (Reuters (via Stockopedia))
  3. Sofinnova closes €725M fund to back Europe's late-stage biotechs (European Biotechnology Magazine)
  4. Growth-Stage Healthcare VC Strategy (Sofinnova Partners)
  5. One of Europe's leading VCs banks a €725M 'crossover' fund (BioPharma Dive)
  6. Sofinnova books biggest-ever $815M fund with an eye toward up-and-coming 'global leaders' (Fierce Biotech)
  7. Europe's life sciences sector gets an $815m vote of confidence from Sofinnova (BioXconomy)
  8. European Tech Champions Initiative (European Investment Fund)
  9. Sofinnova clôture Crossover II à 725 M€ (Capital Finance (Les Echos))
  10. Sofinnova Partners closes Capital XI at €650M (Sofinnova Partners)
  11. Sofinnova Partners closes €725M Crossover II fund to scale European life sciences companies (Tech Funding News)